Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine its functional outcome.
Biotech company BetterLife Pharma Inc., in conjunction with Eurofins Discovery, has obtained its first set of neurological receptor binding data on its lead compound, 2-bromo LSD (TD-0148A), a second-generation LSD derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects, such as hallucinations.
The receptor binding data show binding of TD-0148A to neurological receptors which are known to play key roles in neuropsychiatric disorders.
BetterLife CEO, Dr Ahmad Doroudian, commented: “We are pleased to be partnering with Eurofins Discovery and the global Eurofins Discovery team for these TD-0148A primary and safety pharmacology studies as part of TD-0148A’s IND-enabling preclinical data package.
“TD-0148A is a potential novel new therapy to treat debilitating psychiatric and neurological disorders with high unmet need, such as depression, post-traumatic stress disorder and cluster headaches.
“As the lead compound in BetterLife’s neuropsychiatric pipeline, and protected by several BetterLife owned patents (granted and provisional), BetterLife is fully focused to bring TD-0148A to US IND and the clinic as soon as possible.”
The data show significant TD-0148A binding to serotonin receptors such including 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C, alpha-adrenergic receptors including -1A, -2A, -2B, and -2C, beta-adrenergic receptors, beta-1, and -2, and dopamine receptors D1 and D2S. In contrast, Better Life Pharma notes, there is none to limited binding to receptors such as 5-HT3, GABA-A1, and NMDA receptors. Additional preclinical studies are underway to further determine the functional outcome of the TD-0148A binding at these receptors.
The receptor binding studies are being conducted by Eurofins Discovery at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs.
